Jade Biosciences (JBIO) Return on Capital Employed (2021 - 2026)
Jade Biosciences posted quarterly Return on Capital Employed of 42.78% for Q1 2026, up 2431.0% year-on-year from 1.69% in Q1 2025, and up 2.2% on a QoQ basis from 43.74% in Q4 2025.
Jade Biosciences (JBIO) has 6 years of Return on Capital Employed data on file, last reported at 42.78% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2431.0% year-over-year to 42.78%; the trailing twelve-month figure through Mar 2026 stood at 42.78% (up 2431.0% YoY), and the FY2025 full-year result was 58.3%, down 4173.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 42.78%, up from 43.74% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 3.67% in Q3 2024 and bottomed at 71.6% in Q4 2024.
- The 5-year median for Return on Capital Employed is 23.92% (2022), against an average of 29.88%.
- Peak annual rise in Return on Capital Employed reached 2821 bps in 2024, while the deepest fall reached 5802 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 8.1% in 2022, then sank by 68 bps to 13.59% in 2023, then tumbled by 427 bps to 71.6% in 2024, then jumped by 39 bps to 43.74% in 2025, then grew by 2 bps to 42.78% in 2026.
- The last three Return on Capital Employed figures came in at 42.78% (Q1 2026), 43.74% (Q4 2025), and 46.33% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - | -42.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.78% |
| Dec 31, 2025 | -43.74% |
| Sep 30, 2025 | -46.33% |
| Jun 30, 2025 | -58.85% |
| Mar 31, 2025 | -67.09% |
| Dec 31, 2024 | -71.60% |
| Sep 30, 2024 | 3.67% |
| Jun 30, 2024 | -3.32% |
| Mar 31, 2024 | -22.45% |
| Dec 31, 2023 | -13.59% |
| Sep 30, 2023 | -24.54% |
| Jun 30, 2023 | -20.17% |
| Mar 31, 2023 | -14.64% |
| Dec 31, 2022 | -8.10% |
| Sep 30, 2022 | -31.71% |
| Jun 30, 2022 | -23.92% |
| Mar 31, 2022 | -18.78% |
| Dec 31, 2021 | -12.99% |
| Sep 30, 2021 | -15.42% |